Harmony Biosciences, a US commercial-stage pharmaceutical company, completed the acquisition of Epygenix Therapeutics, a precision medicine-based biopharmaceutical company for $680m. "Harmony shares our team's core values, including a commitment to patients and families living with Dravet syndrome and Lennox-Gastaut syndrome, where a significant unmet need for effective therapies remains. Harmony's demonstrated expertise in drug development and commercialization will accelerate the full potential of these treatments and make a real difference in the lives of Dravet and LGS families," Alex Yang, Epygenix Therapeutics Chair and CEO.